LOS ALTOS, Calif. - TelAve -- QView, Inc., a medical technology leader providing artificial intelligence systems for breast cancer detection, and GEHC have signed a distribution agreement where QView Medical's AI-QVCAD software system will be added to GEHC's portfolio of breast imaging AI solutions for the detection and diagnosis of breast cancer.

Under the definitive agreement, GEHC will market and sell AI-QVCAD for its ABUS – Automated Breast Ultrasound System.

"QView working with GEHC is an excellent example of two organizations leveraging our mutual strengths and technological capabilities to provide a multimodality approach for breast screening. There is no single imaging screening solution," said Bob Wang, President, and CEO of QView, Inc

Mammography misses one-third of the cancers in screening women with dense breast tissue; breast density increases women's cancer risk 4-6 times, affecting more than 40 percent of women¹. Earlier cancer detection is critical to increased survival rates, improved patient care, and reduced cost of care.

More on TelAve News

• Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
• STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
• Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
• Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
• Mandeville Pests May Pose Serious Health Risks for Your Family

The ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. Adding AI-QVCAD software to the ABUS system is a powerful tool in detecting breast cancers earlier when they are more treatable, less invasive treatments, and improve patient quality of life.

Clinicians can now review AI-QVCAD results on the Invenia ABUS Viewer, streamlining clinical workflow and reducing the reading time by up to 33%² while improving clinical outcomes with up to 93%³ sensitivity for lesion detection.

QView Medical supports all efforts to raise awareness of breast density as a significant risk factor - #DENSEBREASTINFO #AREYOUDENSE. QView supports passage of #FINDITEARLY Federal bill requiring health insurers to reimburse for screening and diagnostic breast ultrasound exams – no copay, no deductible.

About QView Medical, Inc.

QView Medical develops AI image-analysis systems for 3D Automated Breast Ultrasound Systems  ABUS). The QView team has been the leader in AI technologies and breast cancer detection for over twenty-five years, including developing R2 mammography CAD, R2 lung CT CAD, U-Systems ABUS, and QView AI QVCAD. Visit our website www.qviewmedical.com for more information.

More on TelAve News

• Share your workplace safety solutions at 2027 Applied Ergonomics Conference
• Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
• May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
• Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
• MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs

--

1. Boyd, et al, NEJM Jan 2007
2. Interpretation Time Using a Concurrent-Read Computer-Aided Detection System for Automated Breast Ultrasound in Breast Cancer Screening of Women with Dense Breast Tissue (Yulei Jiang). Read More: https://www.ajronline.org/doi/10.2214/AJR.18.19516
3. Performance and Reading Time of Automated Breast US with or without Computer-aided Detection. Read More: https://pubs.rsna.org/doi/10.1148/radiol.2019181816